Ventricular Assist Device in Acute Myocardial Infarction

Original Title: Ventricular Assist Device in Acute Myocardial Infarction. Reference: Deepak Acharya et al. J Am Coll Cardiol. 2016;67(16):1871-1880.   Patients undergoing acute myocardial infarction (AMI) with acute cardiac failure or cardiogenic shock have a high mortality rate with the conventional treatment. This study assessed the outcomes of patients with AMI receiving a durable ventricular assist<a href="https://solaci.org/en/2016/04/21/ventricular-assist-device-in-acute-myocardial-infarction/" title="Read more" >...</a>

TAVI in Low-Flow / Low-Gradient

Original Title: Transcatheter Aortic Valve Implantation for Paradoxical Low-Flow Low-Gradient Aortic Stenosis Patients. Reference: Nicolas Debry et al. Catheter Cardiovasc Interv. 2016 Mar;87(4):797-804. Courtesy of Dr. Carlos Fava. Approximately 10 to 13% of low-flow low-gradient severe aortic stenosis cases (LF-LG) have preserved left ventricular function. Its physiopathology remains unclear and it has been associated with a<a href="https://solaci.org/en/2016/04/14/tavi-in-low-flow-low-gradient/" title="Read more" >...</a>

¿Desescalar la doble antiagregación es el nuevo paradigma?

Optimal Duration of Dual Antiplatelet Therapy: New ACC-AHA Guidelines

Original Title: 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients with Coronary Artery Disease. Reference: Levine GN et al. Circulation. 2016 Mar 29. [Epub ahead of print]. Courtesy of Dr. Alejandro Lakowsky. The new ACC-AHAGuidelines on the optimal duration of dual antiplatelet therapy(DAPT) in patients with coronary artery disease have just been<a href="https://solaci.org/en/2016/04/01/optimal-duration-of-dual-antiplatelet-therapy-new-acc-aha-guidelines/" title="Read more" >...</a>

Atrial Fibrillation: Important Impact on TAVI

Original Title: Atrial Fibrillation Is Associated With Increased Mortality in Patients Undergoing Transcatheter Aortic Valve Replacement: Insights From the Placement of Aortic Transcatheter Valve (PARTNER) Trial. Reference: Angelo B. Biviano et al. Circ Cardiovasc Interv. 2016 Jan;9(1):e002766. Courtesy of Dr. Carlos Fava. The conversion to atrial fibrillation (AF) in the context of transcatheter aortic valve replacement<a href="https://solaci.org/en/2016/03/04/atrial-fibrillation-important-impact-on-tavi/" title="Read more" >...</a>

Prevention of Contrast-Induced Nephropathy by Hemodynamic Index–Guided Fluid Administration

Original Titlte: Prevention of Contrast-Induced Nephropathy by Central Venous Pressure–Guided Fluid Administration in Chronic Kidney Disease and Congestive Heart Failure Patients. Reference: GengQian et al. JACC: Cardiovascular interventions 2015 Courtesy of Dr. Agustín Vecchia. Hospital Alemán, Buenos Aires, Argentina. The aim of this study was to assess a venous pressure guided hydration technique in patients with<a href="https://solaci.org/en/2015/12/22/prevention-of-contrast-induced-nephropathy-by-hemodynamic-index-guided-fluid-administration/" title="Read more" >...</a>

TOTAL Trial: The Best on Manual Thrombectomy in AMI Patients

Original title: Randomized Trial of Primary PCI with or without Routine Manual Thrombectomy. Reference: S.S. Jolly et al. for the TOTAL Investigators. N Engl J Med. 2015 Apr 9;372(15):1389-98. Manual thrombectomy is a routine procedure with ST elevation AMI patients. This common practice proved to reduce mortality in the TAPAS study. However, the TASTE study did not observe<a href="https://solaci.org/en/2015/05/20/total-trial-the-best-on-manual-thrombectomy-in-ami-patients/" title="Read more" >...</a>

Mitra-Clip: a valid alternative for high risk patients

Original title: Percutaneous Mitral Valve Repair for Mitral Regurgitation in High-Risk Patients. Results of the EVEREST II Study. Reference: Donald D. Glower et al. J Am Coll Cardiol 2014;64:172-81 Severe mitral regurgitation (MR) often lead to hospitalization for cardiac failure and heart surgery. Half of these patients are rejected for high surgical risk. Percutaneous intervention is a valid<a href="https://solaci.org/en/2014/09/24/mitra-clip-a-valid-alternative-for-high-risk-patients/" title="Read more" >...</a>

TAVR: Regression of Left Ventricular Hypertrophy Decreases Re-hospitalization

Original title: Early Regression of Severe Left Ventricular Hypertrophy After Transcatheter Aortic Valve Replacement Is Associated with Decreased Hospitalization. Reference: Brian Lindman, et al. JACC Cardiovasc Interv 2014;7:662-73.   Left ventricular hypertrophy, defined by the increase of left ventricular mass, has long been associated to increased morbi-mortality in the context of different heart conditions. LV hypertrophy regression might<a href="https://solaci.org/en/2014/08/05/tavr-regression-of-left-ventricular-hypertrophy-decreases-re-hospitalization/" title="Read more" >...</a>

Anillos aórticos pequeños, ¿Qué válvula deberíamos elegir?

Myocardial Damage in MAC

Mitral annulus calcification (MAC) affects between 8% and 23% of the population. It is more common in women and patients with renal insufficiency. This phenomenon is characterized by an increase in valvular annulus fibrosis, which can extend and affect the leaflets. The presence of MAC is associated with valve regurgitation or stenosis, increasing mortality and<a href="https://solaci.org/en/2024/07/18/myocardial-damage-in-mac/" title="Read more" >...</a>

ULTIMATE III: Use of IVUS for Coronary De Novo Lesion Drug Coated Balloon Angioplasty

Percutaneous coronary intervention (PCI) with drug eluting stents (DES) can present limitations, especially in the form of stent thrombosis or instent restenosis (ISR). These findings have furthered the development of drub coated balloons (DCB). The safety and efficacy of DCB have already been shown in the context of ISR and de novo small vessel coronary<a href="https://solaci.org/en/2024/07/12/ultimate-iii-use-of-ivus-for-coronary-de-novo-lesion-drug-coated-balloon-angioplasty/" title="Read more" >...</a>